We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · October 21, 2021

Impact of T-Cell Subset Changes on Anti–PD-1 Efficacy in Metastatic Urothelial Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Anti-PD1 efficacy in metastatic urothelial cancer patients associates with intra-tumoral juxtaposition of T helper-type 1 and CD8+ T-cells
Clin. Cancer Res 2021 Oct 06;[EPub Ahead of Print], M Rijnders, HE Balcioglu, DGJ Robbrecht, AAM Oostvogels, R Wijers, MJB Aarts, P Hamberg, GJLH van Leenders, JA Nakauma-González, J Voortman, HM Westgeest, JL Boormans, R de Wit, M Lolkema, AAM van der Veldt, R Debets

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading